Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for targeting anti-TNF-alpha antibodies

An anti-drug antibody, monoclonal antibody technology, applied in the direction of antibody mimics/stents, antibody medical components, introduction of foreign genetic material using vectors, etc., can solve the problem of increasing the dose or frequency of administration, and impairing the clinical response of anti-TNA-α antibodies Adverse events, etc.

Active Publication Date: 2021-11-12
PORTON BIOLOGICS LTD
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that the presence of ADA impairs the clinical response to anti-TNA-α antibodies and / or triggers adverse events, leading to adverse events including increased dose or dosing frequency, concomitant use of immunomodulatory drugs, discontinuation of treatment, or switching to other TNF-α antagonists. Medical consequences (Atiqi S et al., Front Immunol. 2020;11:312, Homann A et al. J Transl Med (2015) 13:339)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for targeting anti-TNF-alpha antibodies
  • Compositions and methods for targeting anti-TNF-alpha antibodies
  • Compositions and methods for targeting anti-TNF-alpha antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0150] Example 1. Expression of CADAR in human primary T cells.

[0151] A transfer plasmid including the DNA sequence encoding CADAR was designed and synthesized (see the schematic diagram of the structure in figure 2 ), which sequence comprises a scFv derived from adalimumab (scFv-ADL) (Genewiz, NJ). The transfer plasmid was then used to generate VSV-G pseudotyped lentiviral particles using a generation 4 packaging system. Briefly, 293T cells were transfected at 80% confluency with a mixture of transfer plasmid, envelope plasmid, packaging plasmid and Lipofectamine 30000 (Life Technologies). The lentivirus-containing supernatant was harvested after 49 h, filtered through a 0.45 μm PES membrane, concentrated at 1500 × g for 45 min at 4°C, and stored at -80°C.

[0152] Human PBMCs from healthy donors were activated with CD3 / CD28 Dynabeads (Thermo Fisher Scientific) at a 1:1 cell / bead ratio for 24 hours. 2E+6 T cells were transduced with lentiviral particles. T cells were ...

Embodiment 2

[0153] Example 2. In vitro efficacy test of CADAR-T cells.

[0154] Anti-adalimumab (ADL) hybridoma cells were generated by immunizing Balb / c mice with purified scFv-ADL protein. B lymphocytes from mouse spleen fused with myeloma cells. Positive hybridoma clones were screened by three rounds of ELISA. One positive (expressing antibodies against ADL) and one negative (not expressing antibodies against ADL) hybridoma cells in XF T supplemented with 50 U / ml IL-2 (Thermo Fisher Scientific) and 10% FBS (Gibco) Cell expansion medium (STEMCELL Technologies) cultured. Change the medium every 1 to 2 days.

[0155] Positive and negative hybridoma cells were first stained with CFSE (CellTrace, Cat# C34554). 1E+4 hybridoma cells / well were stained with CFSE (2.5 μM) for 10 min at 37°C, washed twice and resuspended in a medium supplemented with 50 U / ml IL-2 (Thermo Fisher Scientific) and 10% FBS (Gibco) XF T cell expansion medium (STEMCELL Technologies).

[0156] CADAR-T cells (8 days...

Embodiment 3

[0162] Example 3. In vivo efficacy test of CADAR-T cells

[0163] After pretreating the mice with intravenous immunoglobulin to minimize FcyR-mediated toxicity against BCR-expressing cells, positive or negative hybridoma cells were injected intravenously into NSG mice. A few days later, CADAR-T cells (or mock T cells) were injected intravenously. Bioluminescence and / or serum ADA were quantified to monitor CADAR-T cell efficacy. CADAR-T cells controlled the growth of positive but not negative hybridoma cells, while mock T cells did not control the growth of positive or negative hybridoma cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides a chimeric anti-drug antibody receptor (CADAR) having specificity for an anti-drug antibody based B cell receptor (BCR), wherein the anti-drug antibody is induced by a therapeutic anti-TNF-alpha monoclonal antibody. The disclosure also provides compositions comprising the CADAR, polynucleotides encoding the CADAR, vectors comprising the polynucleotides encoding the CADAR, engineered cells comprising the CADAR, and methods of using the same.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to PCT Application No. PCT / CN2020 / 102367 filed on July 16, 2020, the disclosure of which is incorporated herein by reference. technical field [0003] The present disclosure generally relates to therapeutics including treatment with immunosuppressive drugs. In particular, the present disclosure relates to compositions and methods for enhancing response to treatment with therapeutic anti-TNF-alpha monoclonal antibodies. Background technique [0004] The use of therapeutic monoclonal antibodies in the treatment of cancer, autoimmune diseases and other indications has undergone a significant expansion in recent years. A well-known side effect associated with therapeutic antibodies is the development of anti-drug antibodies (ADA), which interfere with therapeutic efficacy. ADA can lead to increased clearance of therapeutic antibodies and prevent the drug from binding to its target. Desp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/62C07K19/00C12N15/867C12N5/10A61K39/395A61K35/17A61K45/06A61P29/00A61P19/02A61P17/06A61P19/08A61P1/00A61P1/04A61P17/00A61P27/02
CPCC07K16/241C07K14/70578C07K14/7051C07K14/70503C12N15/86C12N5/0636A61K39/3955A61K45/06A61P29/00A61P19/02A61P17/06A61P19/08A61P1/00A61P1/04A61P17/00A61P27/02C12N2740/15043C12N2510/00C07K2317/56C07K2317/732C07K2319/02C07K2319/03C07K2319/33C07K2319/74A61K2039/505A61K39/4611A61K2239/31A61K39/464402A61K2300/00C07K16/2803C07K2317/622C07K2317/70C07K2317/73A61K38/1774A61K38/177C07K14/70517C07K14/70521A61K38/00A61K2239/13A61K39/4631A61K39/462A61K39/46433A61K2239/21A61K2239/22A61K2239/17C07K2317/21C07K2317/24
Inventor 孔令洁J·王郭天玮朱世诚陈影
Owner PORTON BIOLOGICS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com